Bioniq, a health-tech company leveraging blood biomarker data to provide tailor-made supplements, yesterday announced the closing of a $15M Series B funding program. The oversubscribed round was led by Principal Investors HV Capital and Unbound.

The company is now valued at $75M and the fresh influx of funds will be used to further expand its global market share and continued innovation in the dietary supplements sector.

Bioniq entered the UAE in 2021, and has since expanded across the Gulf region. The company has partnered with Abu Dhabi’s Department of Culture and Tourism, along with Metabolic, a digital therapeutics company, and Al Borg Diagnostics, a leading provider of diagnostic services in Saudi Arabia.

“We’ve entered a new era in nutritional supplementation over the last six years, where it’s become clear that one-size-fits-all solutions are simply inefficient,” said Vadim Fedotov, co-founder and CEO of Bioniq. “Everyone’s health journey is unique. Customers need advanced, adaptable products that provide evolving support for personal health goals. Our AI-driven approach and extensive biochemical database allow us to create customized supplements that provide quantifiable results and cater to individuals’ specific needs”.

Over the last decade, Bioniq has developed a huge biochemical database, leveraging blood test data from clients spanning 5 continents. The AI-powered algorithm used by the company assesses each individual’s height, weight, age, lifestyle, and health goals to create tailor-made supplements that optimize health and address micronutrient imbalances.

Also Read: Advancing MENA Health Through AI Vascular Age Analysis

Bioniq’s supplements are “Swiss-made, pharmaceutical-grade and utilize precise micro-dosing to address bio-individual needs and deficiencies”. Each formula features a unique blend of antioxidants, vitamins, minerals, phytonutrients, amino acids and prebiotics delivered in granules. The supplements are designed to mimic the way the body assimilates food, thus maximizing bioavailability.

“Bioniq’s innovative approach to nutrition is based on the idea that everyone has different nutritional needs and deficiencies, and that generic multivitamins are not enough to address them. We are impressed by Bioniq’s vision and technology, and we believe that they are disrupting the supplement industry with their personalized and science-based approach. We are excited to support them as they grow and scale their business,” explained Shravin Mittal, CEO of Unbound.